|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of SGN-CD19A that can be given to patients with NHL. The safety of this drug
and the effect, if any, SGN-CD19A may have on the disease will also be studied.
SGN-CD19A is designed to attach to a protein called CD19 on the surface of
cancer cells and then release a poison that may cause the cells to die.
This is the first study using SGN-CD19A in humans.